ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Certain chemotherapy drugs block cancer cell division by targeting microtubules—structural polymers that are made of a protein called tubulin and are critical for cell division and other functions. Such microtubule-targeting agents (MTAs) are promising drug candidates against glioblastoma, an aggressive type of brain cancer, but they have not reached the clinic, in part because of highly variable results in the lab. Now, researchers have found one reason why MTAs do not stop the growth of all glioblastoma cells: the levels of tubulin in these cells affect their susceptibility to MTAs (ACS Pharmacol. Transl. Sci. 2019, DOI: 10.1021/acsptsci.9b00045). Lenka Munoz of the University of Sydney and her team measured tubulin levels in 15 glioblastoma cell lines. Then they tested four MTAs that can potentially cross the blood-brain barrier—colchicine, nocodazole, tivantinib, and CMPD1—against the cell lines. In all cases, cells with higher tubulin levels were more susceptible to the drugs. Also, cell lines that survived treatment with three other MTAs had tubulin levels as much as 20% lower than lines that didn’t survive. Why cells have different levels of tubulin is not yet known, Munoz says. But if confirmed in animal models, the results could pave the way for personalized therapy when using MTAs to treat brain cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter